US FDA approves Zevra's treatment for rare genetic disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $21 at Roth/MKM
September 24, 2024 5:40 AM EDTRoth/MKM analyst Jonathan Aschoff raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $21.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "The FDA approved MIPLYFFA for NPC. As ZVRA needs about eight to 12 weeks to make the drug commercially... More
